Investors
OMX Stockholm
( %)
HNSA SEK
Calendar
Upcoming events
06Feb
Full-year Report for January-December 2024
21Mar
Annual Report 2024
17Apr
Interim Report for January-March 2025
Press releases
Our latest press releases
Hansa Biopharma announces positive full results from 15-HMedIdeS-09 Phase 2 study and comparative analysis of imlifidase in patients with Guillain-Barré Syndrome
Regulatory press release
17/12/2024
Hansa Biopharma Completes Enrolment in Global Pivotal Phase 3 Trial of imlifidase in Anti-Glomerular Basement Membrane Disease
05/12/2024
Genethon and Hansa Biopharma announce initiation of a Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome
03/12/2024
Hansa Biopharma to Attend Jefferies London Healthcare Conference
13/11/2024
Hansa Biopharma in brief
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions.
Upcoming
Key progress and look ahead
Progress to date | What’s next 2H ’24 | Looking ahead - 2025 | |
---|---|---|---|
EARLY DEVELEOPMENT | COMPLETED NICE-01 Ph 1safety/tolerability for HNSA-5487 | HNSA-5487 Ph 1 data on exploratory endpoints and clinical development path | HNSA-5487 clinical development |
TRANSPLANTATION | FULL RANDOMIZATION ConfIdeS Ph 3 trial | 15-HMedIdeS-14 data publication in peer reviewed journal | ConfIdeS Ph 3 12 month follow up and BLA submission in 2H Post Approval Efficacy Study readout |
GENE THERAPY | STUDY INITIATED: SRP 9001-104 Ph 1 study (DMD) Genethon (Crigler-Najjar) preclinical AskBio (Pompe) preclinical | Genethon trial initiated (Crigler-Najjar) | SRP 9001-104 Ph 1 study (DMD) initial data readout |
AUTOIMMUNE | TRIAL COMPLETED 15-MedIdeS-09 (GBS) Ph 2 trial 86% ENROLLED GOOD-IDES-12 Ph 3 (anti-GBM) trial | 15-MedIdeS-09 Ph 2 (GBS) data contextualization (IGOS) 16-MedIdeS-12 Ph 2 (AMR) data publication | GOOD-IDES-12 Ph 3 (anti-GBM) 1H full enrolment; 2H data readout |